Endocrine Abstracts

In 24 years old woman in March 2007 was diagnosed acromegaly (somatoprolactinoma) an active phase, hyperprolactinemia. Manifestations: rugged features, amenorrhea, galactorrhea, fasting GH – 144 ng/ml (N<10 ng/ml), IGF-1 – 586 ng/ml (N 48–450 ng/ml), PRL – 6726 mU/l (N 40–530 mU/l). According to pituitary MRT a tumor volume was 14.4 cm3, with supra- and infrasella growth. She was operated in May 2007: transnal transs...

A patient, female, 53 years old was admitted for investigation and treatment of active acromegaly. At the age of 33 on the basis of the clinico-hormonal and CT investigations was diagnosed mixed pituitary adenoma - somatoprolactinoma. GH was 15.4 ng/ml (0–10 in healthy), prolactin (prl) 2000 ng/ml (<580 in healthy). The short course of parlodel therapy had no effect. At the age of 40, she was performed with transsphenoidal adenomectomy. Afterwards, diabetes mellitus (...

Introduction: Acromegaly is a rare chronic disease caused by growth hormone (GH) and insulin-like growth factor 1 type (IRF-1) excess. However, reaching biochemical control of the disease does not always guarantee the improvement of symptoms that play a significant role in the quality of life associated with human health (HRQoL), in particular, patients with acromegaly.Goal: To investigate the quality of life in patients with acromegaly in the Moscow reg...

Aim: To evaluate the frequency and morpho-histological characteristics of the colonic polyps (CP) in acromegaly patients (pts).Materials and methods: We studied 53 pts (50 female, 3 men) aged 23–76 (median – 47) with active acromegaly. The mean disease duration was 10.7±4.3 years. Somatotropinoma was diagnosed in 51 pts and somatoprolactinoma in two. The activity of acromegal? was confirmed on the base of the clinical and hormonal data. Ba...

Aim: To estimate efficiency of long acting somatostatin analog (Oktreotid-Depot, Ltd ‘FarmSyntez’, Russia) in acromegaly treatment.Material and methods: Twenty-five patients with the confirmed acromegaly diagnosis, active phase, receiving Oktreotid-Depot therapy within 6–12 months in a single dose of 20–40 mg/month. Every three months dynamics of clinical signs, basal IGF-1 and GH levels and pituitary adenoma size were analyzed.<p...

Background: Oral octreotide capsules (OOC) are a treatment option for patients with acromegaly in the United States. The MPOWERED trial (NCT02685709) showed that OOC were noninferior to injectable somatostatin receptor ligands (iSRLs; octreotide or lanreotide) in maintenance of biochemical control in patients previously responding to both treatments, as well as demonstrated improvements in patient-reported outcomes among patients receiving OOC.Objective:...

BackgroundMPOWERED, a large phase 3 trial, assessed maintenance of response to oral octreotide capsules (OOC; MYCAPSSA) compared to injectable somatostatin receptor ligands (iSRLs) in patients with acromegaly who responded to OOC and iSRLs (octreotide or lanreotide). OOC were recently approved in the US for patients with acromegaly who responded to and tolerated iSRLs.MethodsEligibility criteria included age ...

BackgroundInjectable somatostatin receptor ligands (iSRLs) have been a mainstay in acromegaly treatment. Oral octreotide capsules (OOC; MYCAPSSA®) were recently approved in the USA. Results from the placebo-controlled CHIASMA OPTIMAL and open-label CH-ACM-01 studies showed an OOC safety profile consistent with that of iSRLs with no new or unexpected safety signals. Results of the MPOWERED trial have enabled a comparison of OOC safety and ...

BackgroundPatients with acromegaly may have high symptom burden. The phase 3 MPOWERED trial assessed control of acromegaly by oral octreotide capsules (OOC; MYCAPSSA®) in comparison to injectable somatostatin receptor ligands (iSRLs) in patients responding to both OOC and iSRLs. iSRLs have been first-line medical treatment for patients with acromegaly for decades. OOC are newly approved in the US for patients previously controlled on iSRL...

BackgroundOral octreotide capsules (OOC; MYCAPSSA®) are approved in the US for individuals with acromegaly who responded to and tolerated treatment with injectable somatostatin receptor ligands (iSRLs). Add-on cabergoline therapy has shown effectiveness in patients previously inadequately controlled with iSRLS.1 The phase 3 MPOWERED trial assessed maintenance of response with OOC compared to iSRLs. Patients receiving OOC and in...